A cost comparison of biologic treatment regimens for metastatic colorectal cancer in Italy
IntroductionBevacizumab is a monoclonal antibody, which, in association with combination chemotherapy regimens, has been shown to be active in metastatic colorectal cancer. Other biologic agents active in the same setting are cetuximab and panitumumab, both of which are monoclonal antibodies directe...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AboutScience Srl
2017-10-01
|
| Series: | Global & Regional Health Technology Assessment |
| Online Access: | http://www.grhta.com/Attach/DE4B1001-B2F7-4844-B4A6-73A98C5DD9C7/2224F4CA-03F8-4058-BD33-55BB7DA5FB21 |